MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -10.2 Million EUR | 57.28% |
| 2022 | -23.88 Million EUR | 36.3% |
| 2021 | -37.49 Million EUR | -171.0% |
| 2020 | -13.83 Million EUR | -373.78% |
| 2019 | 5.05 Million EUR | 606.41% |
| 2018 | -998 Thousand EUR | 82.26% |
| 2017 | -5.62 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -19.63 Million EUR | 28.79% |
| 2024 Q1 | -19.63 Million EUR | -92.36% |
| 2023 FY | -10.2 Million EUR | 57.28% |
| 2023 Q1 | -22.11 Million EUR | 7.42% |
| 2023 Q4 | -10.2 Million EUR | 10.77% |
| 2023 Q3 | -11.43 Million EUR | 48.28% |
| 2023 Q2 | -22.11 Million EUR | 0.0% |
| 2022 Q4 | -23.88 Million EUR | 0.88% |
| 2022 Q3 | -24.09 Million EUR | 19.96% |
| 2022 Q2 | -30.1 Million EUR | 0.64% |
| 2022 Q1 | -30.3 Million EUR | 19.2% |
| 2022 FY | -23.88 Million EUR | 36.3% |
| 2021 Q1 | -9.49 Million EUR | 31.4% |
| 2021 FY | -37.49 Million EUR | -171.0% |
| 2021 Q4 | -37.49 Million EUR | 0.52% |
| 2021 Q3 | -37.69 Million EUR | -301.25% |
| 2021 Q2 | -9.39 Million EUR | 1.03% |
| 2020 Q4 | -13.83 Million EUR | 0.6% |
| 2020 Q1 | 5.41 Million EUR | 0.0% |
| 2020 Q3 | -13.92 Million EUR | 0.0% |
| 2020 FY | -13.83 Million EUR | -373.78% |
| 2019 FY | 5.05 Million EUR | 606.41% |
| 2018 FY | -998 Thousand EUR | 82.26% |
| 2017 FY | -5.62 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -1329.272% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 94.806% |
| Adocia SA | 127 Thousand EUR | 8135.433% |
| Aelis Farma SA | -16.19 Million EUR | 36.975% |
| Biophytis S.A. | 2.7 Million EUR | 477.543% |
| Advicenne S.A. | 12.17 Million EUR | 183.819% |
| genOway Société anonyme | 2.97 Million EUR | 443.26% |
| IntegraGen SA | -709.74 Thousand EUR | -1337.832% |
| Medesis Pharma S.A. | 1.15 Million EUR | 981.101% |
| Neovacs S.A. | -237.08 Thousand EUR | -4204.327% |
| NFL Biosciences SA | -2.27 Million EUR | -348.4% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 334.247% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -1128.707% |
| Sensorion SA | 1.37 Million EUR | 840.447% |
| Theranexus Société Anonyme | 2.44 Million EUR | 517.527% |
| TME Pharma N.V. | -1.07 Million EUR | -845.783% |
| Valbiotis SA | -18.13 Million EUR | 43.74% |
| TheraVet SA | 12.78 Thousand EUR | 79920.102% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 568.119% |
| argenx SE | -1.83 Billion EUR | 99.444% |
| BioSenic S.A. | 28.04 Million EUR | 136.389% |
| Celyad Oncology SA | -6.1 Million EUR | -67.24% |
| DBV Technologies S.A. | -114.95 Million USD | 91.123% |
| Galapagos NV | -157.2 Million EUR | 93.509% |
| Genfit S.A. | -7.61 Million EUR | -34.082% |
| GeNeuro SA | 5.91 Million EUR | 272.662% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 59.362% |
| Innate Pharma S.A. | -30.71 Million EUR | 66.772% |
| Inventiva S.A. | 10.48 Million EUR | 197.292% |
| MedinCell S.A. | 39.5 Million EUR | 125.835% |
| Nanobiotix S.A. | -24.71 Million EUR | 58.714% |
| Onward Medical N.V. | -12.89 Million EUR | 20.855% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 813.47% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 137.617% |
| Oxurion NV | 10.71 Million EUR | 195.285% |
| Pharming Group N.V. | 99.4 Million EUR | 110.266% |
| Poxel S.A. | 44.55 Million EUR | 122.902% |
| GenSight Biologics S.A. | 16.29 Million EUR | 162.63% |
| Transgene SA | -14.4 Million EUR | 29.176% |
| Financière de Tubize SA | 78.62 Million EUR | 112.979% |
| UCB SA | 2.17 Billion EUR | 100.469% |
| Valneva SE | 82.73 Million EUR | 112.334% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 44.909% |